"Cancer"

A new generation of oral selective estrogen receptor degrader, elastostat, has shown promise in clinical studies over standard second-line treatments such as fulvestrant for the treatment of patients with metastatic hormone receptor-positive breast cancer.

Vocal cord cancer often leads to hoarseness, which is a common symptom of many diseases and can be easily overlooked by patients.

The Moffitt Cancer Center & Research Institute is a non-profit cancer treatment and research centre established in 1981 by the Florida Legislature and opened on the campus of the University of South Florida in October 1986.

Many kidney cancer patients want to know whether the disease is hereditary. It is really necessary to learn more about the disease because kidney cancer is one of the common diseases nowadays, so let's take a look at whether kidney cancer can be passed on to the next generation. What abnormalities will kidney cancer cause in the body?

Bladder cancer is one of the common diseases nowadays. The incidence of cancer is still very high and many people are affected by cancer, so some bladder cancer patients want to know if the disease is hereditary

A new approach to cancer treatment!

The US FDA approved a new treatment for non-small cell lung cancer - Tremelimumab + Durvalumab + platinum-based chemotherapy. The triple combination therapy significantly improves efficacy and patient survival and has a good safety profile.

The Dana-Farber Cancer Institute, founded in 1947, is a specialist cancer hospital affiliated with Harvard Medical School, a federally designated comprehensive cancer treatment centre in the United States, and has produced one Nobel Laureate in medicine.

Every year, 40000 women die of breast cancer in the United States alone. When cancers are discovered at an early stage, they can often be cured. Mammography is the best alternative diagnostic method, but this method also has shortcomings. It often results in false positive results, leading to unnecessary surgery.

Recently, the European Commission has approved cemiplimab-rwlc (Libtayo), manufactured by US-based Regeneron, as a monotherapy for the treatment of adult patients with recurrent or metastatic cervical cancer whose disease has progressed during or after platinum-containing chemotherapy. The results of the trial showed that this therapy significantly improved patient survival and had a good safety profile.